within Pharmacolibrary.Drugs.ATC.R;

model R06AA61
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.01,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R06AA61</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dimenhydrinate is an antihistamine used primarily to prevent and treat nausea, vomiting, and dizziness caused by motion sickness. It is a combination of diphenhydramine and 8-chlorotheophylline. The drug is available over-the-counter in many countries and remains widely used for motion sickness and vertigo.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adults, as published data specifically for dimenhydrinate, combinations (R06AA61) are not available; estimates are based on the main active moiety diphenhydramine.</p><h4>References</h4><ol><li><p>Ehling, S, et al., &amp; Papich, MG (2019). Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. <i>Veterinary dermatology</i> 30(2) 91–e24. DOI:<a href=&quot;https://doi.org/10.1111/vde.12727&quot;>10.1111/vde.12727</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30779257/&quot;>https://pubmed.ncbi.nlm.nih.gov/30779257</a></p></li><li><p>Nachum, Z, et al., &amp; Gordon, CR (2006). Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. <i>Clinical pharmacokinetics</i> 45(6) 543–566. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200645060-00001&quot;>10.2165/00003088-200645060-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16719539/&quot;>https://pubmed.ncbi.nlm.nih.gov/16719539</a></p></li><li><p>Culy, CR, et al., &amp; Plosker, GL (2001). Ondansetron: a review of its use as an antiemetic in children. <i>Paediatric drugs</i> 3(6) 441–479. DOI:<a href=&quot;https://doi.org/10.2165/00128072-200103060-00007&quot;>10.2165/00128072-200103060-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11437189/&quot;>https://pubmed.ncbi.nlm.nih.gov/11437189</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R06AA61;
